Metropolitan Life Insurance Company (MetLife)’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,018	Closed	-$397K	–	2619
2020 Q4	$397K	Sell	3,018 -854	-22%	-$75.5K	0.01%	1509
2020 Q3	$196K	Hold	3,872	–	–	﹤0.01%	1790
2020 Q2	$185K	Hold	3,872	–	–	﹤0.01%	1858
2020 Q1	$190K	Hold	3,872	–	–	﹤0.01%	1619
2019 Q4	$222K	Hold	3,872	–	–	﹤0.01%	1843
2019 Q3	$139K	Sell	3,872 -2,242	-37%	-$87.6K	﹤0.01%	2119
2019 Q2	$190K	Hold	6,114	–	–	﹤0.01%	1921
2019 Q1	$143K	Buy	+6,114	New	+$98.1K	﹤0.01%	2110

Metropolitan Life Insurance Company (MetLife)'s EIDX Position: Q1 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 3,018 shares — an estimated $397K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in EIDX in Q1 2019 and held it in 8 quarters. The position peaked at $397K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 3,018 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $397K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
Metropolitan Life Insurance Company (MetLife)'s Eidos Therapeutics, Inc. Common Stock position peaked at $397K in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2021, filed 14 May 2021.